242 related articles for article (PubMed ID: 25012432)
1. Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder: a randomized double blind placebo controlled clinical trial.
Sahraian A; Bigdeli M; Ghanizadeh A; Akhondzadeh S
J Affect Disord; 2014 Sep; 166():201-5. PubMed ID: 25012432
[TBL] [Abstract][Full Text] [Related]
2. Memantine as an Adjuvant Treatment for Obsessive Compulsive Symptoms in Manic Phase of Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Sahraian A; Jahromi LR; Ghanizadeh A; Mowla A
J Clin Psychopharmacol; 2017 Apr; 37(2):246-249. PubMed ID: 28099183
[TBL] [Abstract][Full Text] [Related]
3. Is quetiapine effective for obsessive and compulsive symptoms in patients with bipolar disorder? A randomized, double-blind, placebo-controlled clinical trial.
Sahraian A; Ghahremanpouri B; Mowla A
CNS Spectr; 2022 Oct; 27(5):634-638. PubMed ID: 34027853
[TBL] [Abstract][Full Text] [Related]
4. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder.
Berlin HA; Koran LM; Jenike MA; Shapira NA; Chaplin W; Pallanti S; Hollander E
J Clin Psychiatry; 2011 May; 72(5):716-21. PubMed ID: 20816027
[TBL] [Abstract][Full Text] [Related]
5. Aripiprazole as an adjuvant treatment for obsessive and compulsive symptoms in manic phase of bipolar disorder: A randomized, double-blind, placebo-controlled clinical trial.
Sahraian A; Ehsaei Z; Mowla A
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):267-271. PubMed ID: 29544694
[TBL] [Abstract][Full Text] [Related]
6. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
[TBL] [Abstract][Full Text] [Related]
7. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial.
Roy Chengappa KN; Schwarzman LK; Hulihan JF; Xiang J; Rosenthal NR;
J Clin Psychiatry; 2006 Nov; 67(11):1698-706. PubMed ID: 17196048
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
Weiss EL; Potenza MN; McDougle CJ; Epperson CN
J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
[TBL] [Abstract][Full Text] [Related]
10. Impact of obsessive-compulsive disorder on the antimanic response to olanzapine therapy in youth with bipolar disorder.
Joshi G; Mick E; Wozniak J; Geller D; Park J; Strauss S; Biederman J
Bipolar Disord; 2010 Mar; 12(2):196-204. PubMed ID: 20402712
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.
Dold M; Aigner M; Lanzenberger R; Kasper S
Int J Neuropsychopharmacol; 2015 May; 18(9):. PubMed ID: 25939614
[TBL] [Abstract][Full Text] [Related]
12. Topiramate augmentation in patients with resistant major depressive disorder: a double-blind placebo-controlled clinical trial.
Mowla A; Kardeh E
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):970-3. PubMed ID: 21291943
[TBL] [Abstract][Full Text] [Related]
13. Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder.
Hollander E; Dell'Osso B
Int Clin Psychopharmacol; 2006 May; 21(3):189-91. PubMed ID: 16528143
[TBL] [Abstract][Full Text] [Related]
14. Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial.
Shalbafan M; Malekpour F; Tadayon Najafabadi B; Ghamari K; Dastgheib SA; Mowla A; Shirazi E; Eftekhar Ardebili M; Ghazizadeh-Hashemi M; Akhondzadeh S
J Psychopharmacol; 2019 Nov; 33(11):1407-1414. PubMed ID: 31575326
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological Treatment for Comorbid Bipolar Disorder and Obsessive-Compulsive Disorder in Adults.
Netto VM; Flores CA; Pallanti S
J Psychiatr Pract; 2020 Sep; 26(5):383-393. PubMed ID: 32936585
[TBL] [Abstract][Full Text] [Related]
16. Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study.
Marazziti D; Pfanner C; Dell'Osso B; Ciapparelli A; Presta S; Corretti G; Di Nasso E; Mungai F; Dell'Osso L
J Psychopharmacol; 2005 Jul; 19(4):392-4. PubMed ID: 15982994
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
Koran LM; Ringold AL; Elliott MA
J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
[TBL] [Abstract][Full Text] [Related]
18. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
[TBL] [Abstract][Full Text] [Related]
19. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
Storch EA; Goddard AW; Grant JE; De Nadai AS; Goodman WK; Mutch PJ; Medlock C; Odlaug B; McDougle CJ; Murphy TK
J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
[TBL] [Abstract][Full Text] [Related]
20. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial.
Askari S; Mokhtari S; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
BMC Psychiatry; 2022 Jan; 22(1):34. PubMed ID: 35022014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
